{
  "title": "Khoury ITN006AI: NMS02 Safety of RG2007 (CTLA4-IgG4m) in Patients with Multiple Sclerosis",
  "identifier": {
    "identifier": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY661",
    "identifierSource": "http://www.immport.org"
  },
  "producedBy": {  "name": "Khoury ITN006AI: NMS02 Safety of RG2007 (CTLA4-IgG4m) in Patients with Multiple Sclerosis",
  "performedBy": [
    {
      "firstName": "Samia",
      "lastName": "Khoury",
      "email": "skhoury@partners.org",
      "affiliations": [
          {
             "name": "Brigham and Women's Hospital"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    }
  ],
  "studyGroups": [
        {
          "name": "RG2077.2mg",
          "size": 4
        },
        {
          "name": "RG2077.10mg",
          "size": 4
        },
        {
          "name": "RG2077.20mg",
          "size": 4
        },
        {
          "name": "RG2077.35mg",
          "size": 4
        },
        {
          "name": "RG2077.4x10m",
          "size": 4
        }
  ],
  
  "selectionCriteria": [
        {
          "category": "Inclusion",
          "values": [
              "18 to 55 years of age"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Confirmed diagnosis of MS, defined as an MRI consistent with MS plus two separate clinical events, or one clinical event and MRI consistent with demyelination plus a second MRI demonstrating new lesions"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Have declined all FDS approved therapies for MS"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Systemic steroid treatment within 30 days prior to initial visit (first MRI)"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Interferon, Copaxone, or Tysabri treatment within 60 days prior to initial visit (first MRI)"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Prior treatment with Cytoxan, cladribiine, mitoxantrone, or methotrexate"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Diagnosis of primary progressive MS"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Diagnosis of secondary progressive MS"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Women who are pregnant, nursing or unwilling to practice contraception"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Ongoing upper respiratory, gastrointestinal, or urinary tract infection, or other active infection or malignancy"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Concurrrent serious medical problems that may contraindicate the study procedures"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Claustrophobia or other contraindications to MRI with Gadolinium"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects who are HIV positive"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects who are HBsAg positive"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects who are HCV positive"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects with active CMV"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects who demonstrate a positive PPD"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects with anemia (Hb , 10.5 gm/dl)"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects with thrombocytopenia (platelets /100K/ul)"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects with lymphopenia (platelets/100K/ul)"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Subjects with IgG anti-cardiolipin antibody . 16IU"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Prior exposure to CTLA4-Ig"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Known sensitivity to any ingredients in the study drug"
          ]
        }
  ],
  
  "types": [
      {
          "value": "Interventional"
      }
  ]
  },
  "creators": [
    {
      "firstName": "Samia",
      "lastName": "Khoury",
      "email": "skhoury@partners.org",
      "affiliations": [
          {
             "name": "Brigham and Women's Hospital"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "name": "Immune Tolerance Network",
      "extraProperties": [
        {
          "category": "Catgory",
          "values": [
            {
              "value": "DAIT"
            }
          ]
        },
        {
          "category": "External Id",
          "values": [
            {
              "value": "N/A1"
            }
          ]
        },
        {
          "category": "Description",
          "values": [
            {
              "value": "Immune Tolerance Network"
            }
          ]
        }
      ]
    }
  ],
  
  "primaryPublications": [
    {
      "identifier":
        {
          "identifier": "18794494",
          "identifierSource": "pubmed"
        },
      "authorsList": "Viglietta V(1), Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S,  Guttmann CR, Rusche JR, Khoury SJ.",
      "title": "CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.",
      "publicationVenue": "Neurology.",
      "dates": [
        {
          "date": "2008",
          "type": { "value": "publication year" }
        }
      ]
    }
  ],
  "types": [
      {
        "value": "Clinical Trial"
      },
      {
        "value": "Interventional"
      },
      {
        "value": "Autoimmune"
      }
  ],
  "dates": [
      {
          "date": "2003-01-01",
          "type": {
              "value": "actual_start_date"
          }
      },
      {
          "date": "2015-12-14",
          "type": {
              "value": "final_public_release_date"
          }
      }
  ],
  "availability": "Available for download after registration with ImmPort",
  "refinement": "Curated",
  "dimensions": [{
        "name": {
            "value": "Comprehensive Metabolic Panel"
        }
      },{
        "name": {
            "value": "Blood Cell Count with Differential"
        }
      },{
        "name": {
            "value": "Urinalysis"
        }
      },{
        "name": {
            "value": "Serum Protein Electrophoresis"
        }
      }
      
  ],
  
  "distributions": [
      {
          "identifier": {
              "identifier": "SDY661",
              "identifierSource": "ImmPort"
          },
          "title": "Khoury ITN006AI: NMS02 Safety of RG2007 (CTLA4-IgG4m) in Patients with Multiple Sclerosis",
          "access": {
              "landingPage": "http://www.immport.org",
              "accessURL": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY661",
              "types": [
                  {
                      "value": "Download tab separated files"
                  },
                  {
                      "value": "Download MySQL files and schema"
                  }
              ],
              "authorizations": [
                {
                    "value": "Registraton with ImmPort required"
                }
              ]
          },
          "storedIn": {
              "name": "ImmPort",
              "types": [
                {
                  "value": "primary repository"
                }
              ]
         },
         "licenses": [
           {
             "name": "ImmPort User Agreement",
             "version": "1.0",
             "extraProperties": [
               {
                 "category": "Link to User Agreement",
                 "values": [
                   {
                     "value": "http://www.immport.org/agreement"
                   }
                 ]
               }
             ]
           }
         ]
      }
  ],
  "acknowledges": [
    {
      "identifier": {
        "identifier": ""
      },
      "name": "Immune Tolerance Network",
      "extraProperties": [
        {
          "category": "Link",
          "values": [
            {
              "value": "https://www.fpds.gov/ezsearch/search.do?s=FPDS&q=%22IT+strategy%22+OR+%22enterprise+architecture%22+DEPARTMENT_FULL_NAME%3A%22HEALTH+AND+HUMAN+SERVICES%2C+DEPARTMENT+OF%22+PIID%3A%22HHSD2002011F41972%22+VENDOR_ADDRESS_ZIP_CODE%3A%22221027508%22+GLOBAL_VENDOR_NAME%3A%22GAVER+TECHNOLOGIES++INC.%22+VENDOR_FULL_NAME%3A%22VANGENT%2C+INC.%22+TREASURY_ACCOUNT_SYMBOL%3A%22750885%22+CONTRACTING_OFFICE_NAME%3A%22NIH%2C+NIAID+DEA+OA+OFC+ACQUISITIONS%22+VENDOR_FULL_NAME%3A%22ST.+LOUIS+UNIVERSITY%22+PRODUCT_OR_SERVICE_CODE%3A%22AB93%22+PRINCIPAL_NAICS_CODE%3A%22325414%22+VENDOR_ADDRESS_ZIP_CODE%3A%22277088990%22+PIID%3A%22HHSN266200500019C%22&indexName=awardfull&templateName=1.4.4"
            }
          ]
        }
      ]}
  ],
  "licenses": [
    {
      "name": "ImmPort User Agreement",
      "version": "1.0",
      "extraProperties": [
        {
          "category": "Link to User Agreement",
          "values": [
            {
              "value": "http://www.immport.org/agreement"
            }
          ]
        }
      ]
    }
  ],
  "description": "This study will test the safety of a new drug called RG2077 that is designed to treat MS.  The study will not determine whether RG2077 is effective in treating MS, only whether it is safe."
}
